Deutsche Bank has upgraded CVS Health (NYSE:CVS) to buy from hold, asserting that the company’s earnings and business multiple are "now likely near trough levels" while it has taken measures to improve profitability.

Analysts have set 12-month price targets for CVS Health, revealing an average target of $68.83, a high estimate of $85.00, and a low estimate of $58.00. Surpassing the previous average price target of $66.78, the current average has increased by 3.07%.

Shares of healthcare giant CVS Health (NYSE: CVS) have been in a free fall this year. The company has failed to impress investors with its earnings numbers and has slashed its guidance multiple times.

Shares of healthcare giantCVS Health Corp (NYSE:CVS) are 1.5% higher before the bell, after a bull note at Deutsche Bank. The analyst in question upgraded CVS to "buy" from "hold"

Fintel reports that on December 3, 2024, Deutsche Bank upgraded their outlook for CVS Health (NYSE:CVS) from Hold to Buy. Analyst Price Forecast Suggests 15.72% Upside As of December 2, 2024, the average one-year price target for CVS Health is $68.